Furthermore, with the aim of evaluating the actions of RSV administration on Nrf2 and NF-κB expression in non-dialyzed patients with CKD, the investigators performed a randomized double-blind crossover trial in 20 non-dialyzed patients with CKD, and their results showed that RSV administration at a dose of 500 mg per day for a period of 4 weeks had no antioxidant or anti-inflammatory activity in those subjects [108]. This evidence concerns the gene NFKB1 and chronic kidney disease.